Cell News and Research

RSS

NanoViricides files FluCide pre-IND briefing document with the FDA

NanoViricides, Inc. announced today that it has submitted a pre-IND briefing document to the US FDA. This submission provides the required information for the Company's highly effective anti-influenza drug candidate, FluCide, in support of a pre-IND Meeting.

1 Feb 2012

Certain strains of P. aeruginosa cause WBCs to produce high levels of histamine

Could some cases of asthma actually be caused by an allergic reaction to a common environmental bacteria? New research findings published in the Journal of Leukocyte Biology suggests that this idea may not be as far-fetched as it seems. In a research report appearing in the February 2012 print issue, researchers show a link between common environmental bacteria and airway inflammation.

1 Feb 2012

CartiHeal secures $5M in venture funding

CartiHeal (2009), Ltd, a privately held medical device company, focused on developing and bringing to market a proprietary, off-the-shelf, and cell-free cartilage regeneration technology, announced that it raised $5 million in venture funding from two US-Israeli venture capital firms, Accelmed and Access Medical Ventures. The financing will be used to prepare its first product launch early 2013 in Europe.

1 Feb 2012

Crizotinib can treat ROS1-driven tumors

A report from investigators at the Massachusetts General Hospital (MGH) Cancer Center has defined the role of a recently identified gene abnormality in a deadly form of lung cancer. Tumors driven by rearrangements in the ROS1 gene represent 1 to 2 percent of non-small-cell lung cancers (NSCLC), the leading cause of cancer death in the U.S.

1 Feb 2012

Kras gene plays a role in continuous growth of pancreatic cancer

A mutant protein found in nearly all pancreatic cancers plays a role not only in the cancer's development but in its continued growth, according to a new study from University of Michigan Comprehensive Cancer Center researchers. The finding suggests a possible target for developing new ways to treat this deadly disease.

1 Feb 2012

Nanosize titanates may inhibit growth of oral cancer and bacterial cell lines

Sometimes bigger isn't better. Researchers at the U.S. Department of Energy's Savannah River National Laboratory have successfully shown that they can replace useful little particles of monosodium titanate (MST) with even tinier nano-sized particles, making them even more useful for a variety of applications.

1 Feb 2012

New technology helps scientists observe Parkinson's cell development

In the US alone, at least 500,000 people suffer from Parkinson's disease, a neurological disorder that affects a person's ability to control his or her movement. New technology from the University of Bonn in Germany lets researchers observe the development of the brain cells responsible for the disease.

1 Feb 2012

Researchers investigate Avian Pathogenic E. coli strains

Escherichia coli bacteria thrive in the lower intestine of humans and other animals, including birds. Most are vital constituents of the healthy gut flora, but certain forms of E. coli cause a range of diseases in both humans and poultry.

1 Feb 2012

IMUC president to present at Immunotherapeutics Partnering and Deal Making Conference

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that its president and CEO, Manish Singh Ph.D., will be presenting at the Immunotherapeutics Partnering and Deal Making Conference, which will take place in San Diego, California on January 30-31, 2012.

31 Jan 2012

Sigma-Aldrich acquires BioReliance

Sigma-Aldrich Corporation, a leading Life Science and High Technology company, announced it has completed its acquisition of BioReliance Holdings, Inc., a leading provider of global biopharmaceutical testing services, from Avista Capital Partners for $350 million in cash, subject to normal post-closing adjustments.

31 Jan 2012

Small molecules at the cell’s membrane enable cell movement

Cell biologists at Johns Hopkins have identified key steps in how certain molecules alter a cell’s skeletal shape and drive the cell’s movement.

31 Jan 2012

Oral HPV infection more common in men than women: Study

According to a new US study, oral human papillomavirus (HPV) infection is more common among men than women, leading to an increased risk for men of head and neck cancers. HPV causes the majority of cervical cancers, as well as genital and anal - and head and neck cancers.

31 Jan 2012

Roche’s skin cancer drug Erivedge gets FDA nod

The Food and Drugs Administration (FDA) this Monday approved a pill that treats the most common type of skin cancer, basal cell carcinoma.

31 Jan 2012

Interim results from Allos Therapeutics' FOLOTYN and bexarotene Phase 1 combination study on CTCL

Allos Therapeutics, Inc. today reported interim results from the Company's ongoing Phase 1 combination study of FOLOTYN and bexarotene in patients with relapsed or refractory cutaneous T-cell lymphoma.

31 Jan 2012

Haemonetics third quarter net income decreases 8% to $18.3M

Haemonetics Corporation today reported third quarter 2012 GAAP net revenue of $191.2 million, up 8%, net income of $18.3 million, down 8%, and diluted earnings per share of $0.72, down 7%.

31 Jan 2012

Lycopene can kill prostate cancer cells

A nutrient in cooked tomatoes has been shown in laboratory studies to slow the growth of or even kill prostate cancer cells.

31 Jan 2012

ESC welcomes 'intriguing' study on heart failure

The European Society of Cardiology (ESC) welcomes an "intriguing" study, published today in the Journal of the American College of Cardiology, featuring a completely novel approach for improving endothelial function in heart failure.

31 Jan 2012

HSP40/70 linked to hepatitis C infection

Researchers from UCLA's Jonsson Comprehensive Cancer Center have identified a cell-permeable peptide that inhibits a hepatitis C virus protein and blocks viral replication, which can lead to liver cancer and cirrhosis.

31 Jan 2012

New HIS guidelines to minimize surgical infections in day centers, primary care

New guidelines from the Healthcare Infection Society (HIS) aimed at minimising surgical infection in day centers and primary care are now published in the Journal of Hospital Infection.

31 Jan 2012

Anti-HER2 dendritic cell vaccine shows promise against DCIS

Researchers at the Perelman School of Medicine at the University of Pennsylvania report that a short course of vaccination with an anti-HER2 dendritic cell vaccine made partly from the patient's own cells triggers a complete tumor eradication in nearly 20 percent of women with ductal carcinoma in situ (DCIS), an early breast cancer.

31 Jan 2012